BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
DTSTART:20200329T030000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZNAME:CEST
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20201025T020000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZNAME:CET
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20260409T031819Z
UID:1591799400@ist.ac.at
DTSTART:20200610T163000
DTEND:20200610T174500
DESCRIPTION:Speaker: Curt Bilby\nhosted by Alexander Schwartz\nAbstract: Ab
 stractTechnology commercialization has been with us for decades. While the
  processes\, protocols and models are becoming more refined and better und
 erstood\, the path is still full of challenges\, failures and rewards. Suc
 cessful technology commercialization often requires a unique mindset and a
 pproach\, calling us to bridge the gap between universities\, businesses\,
  investors\, and governments\, but we do not always speak the same languag
 e.Let us share and discuss some behind-the-scene examples that might allow
  us to reset some of our expectations.BiographyCurt Bilby has over twenty-
 five years of executive leadership experience in both the US and Europe fo
 cused on technology commercialization\, company growth and shareholder val
 ue across several markets and technologies.Dr. Bilby is currently the Pres
 ident and CEO of Art Analysis & Research - the leading provider of scienti
 fic testing of artworks to support authentication. Previous to his venture
  in the art market\, he was the President and CEO of Terapio Corporation\,
  a biopharmaceutical company developing a countermeasure for radiation and
  chemical poisoning in mass casualty situations based on university techno
 logy. Prior to that\, Dr. Bilby was President and CEO of Seahawk Biosystem
 s Corporation\, which commercialized a biosensor for pathogen detection ba
 sed on technology developed at the Naval Research Laboratory. He was the C
 hairman and CEO of Evacyte Corporation\, a company that commercialized a l
 aser-based cancer detection and cell diagnostic founded on university tech
 nology. Dr. Bilby also served as the Président-Directeur Général of Eur
 imed\, S.A. headquartered in Paris\, France.Dr. Bilby has engineering degr
 ees from Rose-Hulman Institute of Technology and Auburn University and con
 ducted his doctoral work at The University of Texas at Austin. Of note is 
 his selection as a Distinguished Young Alumnus of Rose-Hulman where he was
  also awarded an honorary doctorate.   In order for us to track the regi
 strations\, please register here (https://istaustria.microsoftcrmportals.c
 om/event/registration?id=TWIST_Talk_by_Curt_Bilby_Technology_Commercializa
 tion939261923). You can directly join the webinar without registration vi
 a the links below:Zoom Desktop Client (https://istaustria.zoom.us/j/944782
 50076?pwd=dXVUVVU2dzhTb0RTTFB3bXdzS0Rrdz09)Zoom Browser Client (https://is
 taustria.zoom.us/wc/join/94478250076?pwd=dXVUVVU2dzhTb0RTTFB3bXdzS0Rrdz09)
LOCATION:Webinar\, ISTA
ORGANIZER:thomas.zauner@ist.ac.at
SUMMARY:Curt Bilby: TWIST Talk by Curt Bilby
URL:https://talks-calendar.ista.ac.at/events/2777
END:VEVENT
END:VCALENDAR